Our results show a significant reduction of total MBCs and switched MBC subpopulations in RA patients treated with the CTLA-4-Ig compared to controls; moreover, the frequency of plasma blasts was lower in both CTLA-4-Ig and TNF-α inhibitor-treated patients even if the difference was not significant. This evidence concerns the gene CTLA4 and rheumatoid arthritis.